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Objective. To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA).
Methods. A total of 24,081 patients with OA or RA who had a moderate or high risk for CV disease were enrolled internationally into a double-blind randomized controlled trial. Interventions included celecoxib at a dosage of 100-200 mg twice daily, ibuprofen at a dosage of 600-800 mg 3 times daily, or naproxen at a dosage of 375-500 mg twice daily. The main outcomes were the first occurrence of a major adverse CV event, GI event, or renal event, and mortality.
Results. In the subgroup of patients with OA, the risk of a major adverse CV event was significantly reduced when celecoxib was compared with ibuprofen (hazard ratio [HR] 0.84, 95% confidence interval [95% CI] 0.72-0.99), but no significant difference was observed when celecoxib was compared with naproxen. In the RA subgroup, comparisons of celecoxib versus ibuprofen and celecoxib versus naproxen for the risk of major adverse CV events revealed HRs of 1.06 (95% CI 0.69-1.63) and 1.22 (95% CI 0.78-1.92), respectively. In the OA subgroup, comparisons of celecoxib versus ibuprofen for the risk of GI events showed an HR of 0.68 (95% CI 0.51-0.91), and a comparison of celecoxib versus naproxen showed an HR of 0.73 (95% CI 0.55-0.98). Duplicate comparisons in patients with RA revealed HRs of 0.48 (95% CI 0.22-1.07) and 0.54 (95% CI 0.24-1.24), respectively. In patients with OA, a comparison of celecoxib versus ibuprofen for the risk of renal events showed an HR of 0.58 (95% CI 0.40-0.82). In patients with RA, celecoxib treatment was associated with significantly lower mortality compared with naproxen treatment (HR 0.47, 95% CI 0.25-0.88).
Conclusion. Treatment with celecoxib at approved dosages conferred a similar or lower risk of CV, GI, and renal adverse events compared with treatment with ibuprofen or naproxen in patients with OA and patients with RA.
Nonsteroidal antiinflammatory drugs (NSAIDs) are effective for the treatment of joint pain in patients with osteoarthritis (OA) and those with rheumatoid arthritis (RA). In the US alone, health care workers write more than 100 million NSAID prescriptions annually (1) , and 50% of patients with arthritis require daily treatment with some type of analgesic (2, 3) . Many pharmacologic and nonpharmacologic options exist. NSAIDs represent the most widely used medications because of their established analgesic benefit, but the relative safety across members of this drug class is less certain. Selecting the most appropriate analgesic can challenge treating clinicians because of the variable effectiveness and safety of these agents.
Previous studies underscored the risk of cardiovascular (CV) events associated with selective cyclooxygenase 2 (COX-2) inhibitors, leading to the withdrawal of rofecoxib (4). However, controversy remained regarding the CV-related safety of the selective COX-2 inhibitor, celecoxib (5, 6) . In 2005, the US Food and Drug Administration (FDA) strengthened the warning for adverse CV events for all non-aspirin NSAIDs. Subsequent studies further questioned the safety of nonselective NSAIDs (7) (8) (9) . In addition, the relative safety of nonselective NSAIDs associated with the relative gastrointestinal (GI) and renal safety of different NSAIDs remains poorly defined. These issues are critical for patients with OA and patients with RA, who already have a higher risk of adverse CV events compared with the general population and often experience multiple comorbidities (10, 11) .
Based on these concerns, Pfizer initiated a CV safety trial, the Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECI-SION) trial, in order to provide new, more definitive and useful information for patients, providers, and regulators about the safety of celecoxib and NSAIDs. The PRECI-SION trial, a global safety study among patients with OA or RA, enrolled >24,000 patients worldwide (12) . The recently published results demonstrated the noninferiority of moderate doses of celecoxib compared with moderate doses of ibuprofen and naproxen with respect to CV safety based on an intent-to-treat (ITT) analysis. Furthermore, an on-treatment analysis including follow-up time while being treated with the study drug demonstrated better safety of celecoxib for GI end points compared with ibuprofen and naproxen. For renal end points, celecoxib exhibited increased safety only when compared with ibuprofen (13). However, previously published studies did not uniformly demonstrate an increased risk of adverse CV events in patients with RA receiving selective COX-2 inhibitors (14) . Our group conducted analyses in the prespecified OA and RA subgroups to further define the relative CV, GI, and renal safety associated with celecoxib compared with ibuprofen and naproxen in these common types of arthritis.
PATIENTS AND METHODS
Study design and study population. Briefly, the PRECI-SION trial was a noninferiority trial designed to assess the risk of CV events associated with celecoxib compared with the risk associated with commonly used NSAIDs (e.g., ibuprofen and naproxen). The trial was conducted at 923 centers in the US, Canada, Australia, Brazil, Colombia, Costa Rica, Mexico, Panama, Peru, Philippines, Taiwan, Hong Kong, and Ukraine from October 2006 to April 2016. The Institutional Review Board/Independent Ethics Committee at each study site approved the trial, and all patients provided written informed consent before participating. The trial could not be performed in Europe because of restrictions placed on the prescribing of coxibs by the European Medicines Agency.
Eligible patients included those who were at least 18 years of age and had clinically diagnosed OA or RA for a duration of at least 6 months (15) (16) (17) and who required long-term daily therapy with an NSAID. Participants were required to have established CV disease or CV risk factors. These risk factors included a known history of a major adverse CV event, occlusive disease of the coronary and non-coronary arteries, a clinical diagnosis of diabetes, or evidence of CV risk based on concomitant risk factors, including age ≥65 years in women and >55 years in men, hypertension, dyslipidemia, left ventricular hypertrophy, microalbuminuria, urine protein:creatinine ratio of >2, an ankle-brachial index of <0.9, cigarette smoking, a waist-to-hip ratio of ≥0.90, and a family history of premature CV disease. Exclusion criteria included any of the following CV events within 3 months prior to enrollment: major adverse CV event, unstable angina, electrophysiologic evidence of unstable cardiac rhythm, or any major surgery; planned coronary, CV, or peripheral revascularization; New York Heart Association class III or IV heart failure (18) or known left ventricular dysfunction with an ejection fraction of ≤35%; active significant GI, hepatic, renovascular, or coagulation disorder; history of acute joint trauma; allergy or hypersensitivity to celecoxib, ibuprofen, naproxen, or aspirin; poor response to disease-modifying antirheumatic drug or oral corticosteroid treatments; and requirement for treatment with medications excluded during the course of the study. Women were excluded if they were pregnant, might become pregnant, or were lactating. Additional selection criteria are shown in Supplementary Study protocol. Patients who met the entry criteria and were willing to provide informed consent were randomized in a double-blind manner to receive celecoxib 100 mg twice daily in patients with OA and up to 200 mg twice daily in patients with RA, ibuprofen 600-800 mg 3 times daily, or naproxen 375-500 mg twice daily with matching placebos (1:1:1 allocation). Dose escalation was allowed at the discretion of the patient and investigator if symptom relief was not adequate. The allocation of patients is illustrated in a CONSORT diagram in Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40400/ abstract. Randomization was stratified according to geographic region, low-dose aspirin use (yes or no), and arthritis type (OA or RA) and implemented using an interactive voice response system. All patients were provided open-label esomeprazole at a dosage of 20-40 mg/day and were allowed to receive aspirin (≤325 mg/day, with 75-100 mg considered to be optimal for protection against CV events and recommended for the prevention of CV events) (see Supplementary Table 4 ). After randomization and the baseline visit, patients had scheduled visits at months 1, 2, 4, 8, and 12 and every 6 months thereafter until month 42. Study patients were required to complete at least 18 months of follow-up visits. Follow-up visits included clinical assessments and laboratory testing as well as identification of new adverse events or changes in CV, renal, and GI status, and arthritis outcomes.
The primary end point of the parent study was the first occurrence of a composite end point consisting of CV death, nonfatal myocardial infarction, or nonfatal stroke, which is identical to the primary composite end point of the Antiplatelet Trialists Collaboration (APTC). Trial completion required collection of a specific number of primary end points: 580 primary end points for the ITTanalysis and 420 end points for the on-treatment analysis (analysis of patients receiving the assigned treatments). Sample size calculations estimated that >20,000 patients would be required to meet these goals. In order to reach the requisite number of end points, >24,000 patients were ultimately enrolled.
In the current analyses, findings in patients with OA and patients with RA were reported separately. The primary outcomes for these 2 subgroups were based on an ITT analysis, with the on-treatment analysis used as a sensitivity analysis. Analyzed outcomes included major adverse CV events (APTC event plus revascularization or hospitalization for transient ischemic attack or unstable angina) plus clinically significant GI, renal, and allcause mortality events. Clinically significant GI events were defined as gastroduodenal hemorrhage; gastric outlet obstruction; perforation of the gastroduodenum, small bowel, or large bowel; hemorrhage of the large bowel, small bowel, or acute GI hemorrhage of unknown origin; new-onset iron deficiency anemia; or symptomatic gastric or duodenal ulcer. Clinically significant renal events included development of renal insufficiency or renal failure, defined based on development of any of the following: serum creatinine level of ≥2.0 mg/dl and an increase of ≥0.7 mg/dl from baseline; hospitalization for acute renal failure with a doubling of the baseline serum creatinine level or hyperkalemia with a ≥50% increase in the serum creatinine level; or initiation of dialysis. A Clinical Events Committee adjudicated all of the above end points in a blinded manner, using prespecified definitions.
The analgesic efficacy of the treatments was evaluated at baseline and follow-up using the pain score on a visual analog scale (VAS). For the assessment of function, patients completed the Health Assessment Questionnaire disability index (HAQ DI) (19) at baseline, at months 1, 12, 24, 36, and 42, and at the time of premature study drug discontinuation, if applicable. All patients who discontinued the study drug treatment were followed up per protocol through month 42 or to study completion, whichever occurred first.
Statistical analysis. The primary analyses in the PRECISION trial assessed noninferiority for the frequency of adverse CV events during treatment with celecoxib versus treatment with naproxen and ibuprofen. The current analyses focused on the OA and RA subgroups. Noninferiority hypotheses were not tested, and no adjustments were made for multiple comparisons. Furthermore, no adjustment to the value of alpha was made to account for multiple comparisons, because each comparison was assumed to be independent. For comparisons between groups, P values less than 0.05 were considered significant. The P value threshold of <0.10, based on nominal P values, was considered significant for the interaction between * The major adverse cardiovascular (CV) event (MACE) end point is defined as the first occurrence of CV-related death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for unstable angina, revascularization, or hospitalization for transient ischemic attack. The Antiplatelet Trialists Collaboration (APTC) end point is defined as the first occurrence of CV-related death, nonfatal MI, or nonfatal stroke. All major safety events include MACE, composite serious gastrointestinal (GI) and renal events, and all-cause mortality. Composite serious GI events include gastroduodenal hemorrhage, gastric outlet obstruction, gastroduodenal small or large bowel perforation, small or large bowel hemorrhage, acute GI hemorrhage, symptomatic gastric or duodenal ulcer or anemia (defined as a decrease in the hemoglobin concentration of ≥2 gm/dl or hematocrit ≥10% with no clinical evidence of acute GI bleed and biochemical evidence of iron deficiency). All major safety events include MACE, composite serious GI events, renal events, and all-cause mortality. Values are the number (%).
type of arthritis (OA/RA) and treatment. Cumulative event curves were constructed for each of the 3 treatment arms, in the OA and RA subgroups separately. Hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) comparing treatment groups for the 4 safety outcomes of interest were calculated using Cox proportional hazards regression models, with adjustment for stratification factors (geographic region and lowdose aspirin use). An interaction between treatment group and arthritis type was tested in the Cox models for each drug-to-drug comparison by adding the interaction term to the model. Analyses were censored after 30 months in the ITT population and after 43 months in the on-treatment population. All analyses were performed using SAS version 9.4.
RESULTS
Among the 24,081 patients enrolled in the PRECI-SION trial, 89.9% (n = 21,645) had OA and 10.1% (n = 2,436) had RA. The mean age of the patients with OA was 64 years, and 63% were female (Table 1) . Twenty-three percent of those with OA had experienced a previous CV event; 47% used daily aspirin, and 18% smoked cigarettes. The 3 treatment arms were well balanced among patients with OA. In contrast, patients with RA were slightly younger than those with OA, with a mean age of 61 years, Figure 1 . Time-to-event analysis of primary and secondary outcomes in patients with osteoarthritis and patients with rheumatoid arthritis, showing cumulative event rates across the 3 treatment arms. A and B, Major adverse cardiovascular events (MACEs). C and D, Gastrointestinal events. E and F, Renal events. G and H, All-cause mortality. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) and P values were calculated using Cox proportional hazards regression models with adjustment for stratification factors. and 73% were female (Table 1) . Similar to patients with OA, 24% of those with RA had a previous CV event, but fewer used daily aspirin (37%), and slightly more smoked cigarettes (21%). Allocation of the patients with RA to the 3 treatment arms was well balanced. Use of an increased dosage of the 3 treatments was similar in the RA subgroup, but for regulatory reasons, the protocol did not permit celecoxib up-titration in the OA subgroup, resulting in different proportions of patients using the maximum allowable dosages (see Supplementary Table 5 , available on the Arthritis & Rheumatology web site at http://online library.wiley.com/doi/10.1002/art.40400/abstract). The mean AE SD doses in the OA group were as follows: celecoxib 100 AE 3 mg, naproxen 426 AE 52 mg, and ibuprofen 681 AE 82 mg. In the RA group, the doses were celecoxib 141 AE 42 mg, naproxen 425 AE 52 mg, and ibuprofen 681 AE 82 mg. Among patients with OA, the percentages in whom NSAIDs were up-titrated were as follows: 0.3% of those receiving celecoxib, 55.3% of those receiving naproxen, and 55.3% of those receiving ibuprofen. Among patients with RA, the percentages were 56%, 54.9%, and 56.5%, respectively.
The frequency of adjudicated clinical end points is shown in Table 2 . Among patients with OA, 4.4% met the major adverse CV event end point compared with 4.8% of those with RA (P = 0.30). The cumulative incidences for the 3 treatment arms in patients with OA and patients with RA are shown in Figures 1A and B . There were significantly fewer major adverse CV events in the OA subgroup when comparing celecoxib to ibuprofen (HR 0.84, 95% CI 0.72-0.99), but not among the RA group (HR 1.06, 95% CI 0.69-1.63). The treatment-by-arthritis-type (OA versus RA) interaction was not significant (P = 0.29). In both the OA group and the RA group, the risk of a major adverse CV event did not differ significantly between those randomized to receive celecoxib and those randomized to receive naproxen.
The frequency of adverse GI events was similar in patients with OA and patients with RA (1.35% versus 1.77%; P = 0.096) ( Table 2 ). The frequency of adverse GI events in patients with OA was 1.06% in those randomized to receive celecoxib, 1.54% in those randomized to receive ibuprofen, and 1.45% in those randomized to receive naproxen. A similar pattern was observed in patients with RA, with 1.11% in those randomized to receive celecoxib, 2.28% in those randomized to receive ibuprofen, and 1.90% in those randomized to receive naproxen. The cumulative event curves for adverse GI events are shown in Figures 1C and D . The HRs comparing celecoxib with ibuprofen (0.68, 95% CI 0.51-0.91) and comparing celecoxib with naproxen (0.73, 95% CI 0.55-0.98) demonstrated a significantly reduced risk of an adverse GI event in patients with OA randomized to receive celecoxib. Patients with RA showed a similar pattern of GI risk, with reduced risk comparing celecoxib with ibuprofen (HR 0.48, 95% CI 0.22-1.07) and celecoxib with naproxen (HR 0.54, 95% CI 0.24-1.24), but neither comparison excluded null values. Treatment according to arthritis type interactions did not differ significantly (P > 0.10 for both).
The frequency of adverse renal events was 0.89% in patients with OA and 1.15% in patients with RA (P = 0.20) ( Table 2 ). The cumulative incidence for OA showed fewer renal events in patients receiving celecoxib ( Figure 1E ). The risk of renal adverse events in patients with OA was lower in those randomized to celecoxib than that in those randomized to ibuprofen (HR 0.58, 95% CI 0.40-0.82) and was numerically lower but not statistically different between celecoxib and naproxen (HR 0.77, 95% CI 0.53-1.12). The cumulative event curve for RA showed no differences across treatment arms ( Figure 1F ) and the HRs demonstrated no differences in risk across agents. The interaction between treatment group and arthritis type did not reach statistical significance (HR 0.47, 95% CI 0.25-0.88) ( Figure 1H ). The interaction between celecoxib versus naproxen and arthritis type met the criteria for statistical significance (P for interaction = 0.07).
The primary analysis was an ITT analysis, but we also performed on-treatment analyses (Figure 2) . The results of the on-treatment analysis qualitatively resembled those of the ITT analysis, with most estimates showing somewhat larger differences. An exploratory analysis also assessed a composite end point of all major safety events, including major adverse CV events, serious GI or renal events, and all-cause mortality. The frequency of this end point was higher in patients with RA than in patients with OA (8.37% and 6.96%, respectively; P = 0.01) ( Table 2 ). In the OA subgroup, the HRs comparing celecoxib versus ibuprofen (0.80, 95% CI 0.70-0.90) and celecoxib versus naproxen (0.90, 95% CI 0.80-1.03) showed fewer major safety events with celecoxib. The HRs for the RA subgroup did not show any difference in the risk of major safety events between treatment arms. The interactions between treatment group and arthritis type for this end point were not statistically significant (P > 0.10 for all comparisons).
Finally, we examined functional status as measured by the HAQ DI and pain score on a VAS (see Supplementary Figure 2) . At baseline, patients with OA had higher mean AE SD pain scores on a VAS (54.3 AE 23.6 mm versus 51.9 AE 24.9 mm in patients with RA; P < 0.001). The improvements in the pain score in patients with OA were similar across treatment arms. Patients with RA treated with ibuprofen had statistically significantly greater improvement in pain compared with patients with RA treated with celecoxib (P = 0.02), but the modest difference had unclear clinical significance. As observed for the pain score, patients with OA had similar changes in HAQ DI scores across treatment arms, but among patients with RA, it was slightly better for those receiving ibuprofen compared with those treated with celecoxib (P = 0.02).
DISCUSSION
Arthritis is the most common cause of disability in the US. In 2014,~15 million arthritis patients requiring treatment with analgesics reported severe joint pain (20) . In 2000, more than 100 million NSAID prescriptions were written in the US (21) . NSAIDs differentially affect COX isoforms, potentially accounting for the benefits and varying toxicities across agents. The PRECISION trial demonstrated similar CV safety for moderate doses of the selective COX-2 inhibitor celecoxib and the nonselective NSAIDs ibuprofen and naproxen (13) . In a set of analyses in prespecified subgroups according to type of arthritis (OA and RA), we observed fewer major adverse CV events in patients with OA treated with celecoxib compared with those treated with ibuprofen. Patients with OA treated with celecoxib also experienced less GI toxicity than those treated with ibuprofen or naproxen; this was not observed in RA, but the statistical power in that subgroup was limited. Adjudicated renal adverse events were less common in celecoxib-treated compared with ibuprofen-treated patients with OA but not patients with RA.
These subgroup analyses add important and clinically relevant information to our understanding of the safety of selective and nonselective NSAIDs in patients with OA and patients with RA. The findings regarding CV safety in both OA and RA provide reassurance to those being treated with celecoxib and those considering celecoxib treatment. Because RA is associated with a 1.5-2.0 times greater risk of CV events, presumed in part to the chronic systemic inflammatory nature of RA (which may promote plaque instability and major adverse CV events), the safety of different NSAIDs in patients with RA might differ from that in patients with OA (22) . The results presented herein suggest a slightly lower CV risk for celecoxib users with OA compared with ibuprofen users with OA; however, a similar CV risk was observed when comparing the different NSAIDs in RA patients. As expected, the frequency of adverse events was higher in patients with RA than in patients with OA. These findings support the efforts underway to refine risk stratification and CV management strategies in RA.
Patients treated with celecoxib also had a reduced risk for other end points. Among patients with OA, the risk of GI adverse events was significantly lower in those treated with celecoxib than in those receiving either ibuprofen or naproxen. This finding is not surprising based on the results of prior meta-analyses (23), but most individual studies have not clearly demonstrated improved GI safety of celecoxib (24) . Similar to the frequency of CV events observed in patients with RA, the frequency of GI events in patients with RA in the current study was higher than that in patients with OA (25) . The reduced all-cause mortality among patients with RA treated with celecoxib compared with naproxen was not anticipated. The number of deaths was relatively small in each group: 15 in the celecoxib group (1.85%) and 30 in the naproxen group (3.79%), thus precluding strong conclusions. This reduction resulted from a combination of reduced mortality across various causes (i.e., infection, cancer, respiratory) (see Supplementary  Table 6 ). Further examination of these deaths is underway, but this finding may have resulted from chance. Future studies of cause-specific mortality that includes more events will be helpful; such studies will likely require the use of observational data sets.
The PRECISION trial was conducted as a randomized, double-blind, active drug-controlled trial. Randomization was stratified based on the underlying arthritis diagnosis (OA or RA) and whether patients were receiving aspirin as prophylaxis against CV events. The trial was powered based on the total number of events across all patients and not on the size of each subgroup; therefore, the statistical power for some subgroup analyses does not permit drawing firm conclusions. The ITT population was chosen for the primary analysis, but the on-treatment population showed directionally similar results (see Figure 2) , some of which were statistically significant, while others were not. The withdrawal rate during the PRECISION trial was higher than expected but was similar across treatment arms among all patients and also in the OA and RA subgroups (see Supplementary Figure 3) . Dosing of the 3 treatments was slightly different in the OA and RA subgroups based on limitations imposed by drug regulators for using celecoxib 100 mg twice daily in the OA subgroup; this issue may have influenced the results. Prior studies have demonstrated an increased risk of adverse effects with celecoxib as well as nonselective NSAIDs at higher dosages (9, 26, 27) .
In conclusion, these subgroup analyses of the PRE-CISION trial, based on the underlying arthritis diagnosis, yield results that are similar but not identical to those of the overall trial. The OA subgroup randomized to receive celecoxib treatment experienced fewer CV events compared with the subgroup randomized to ibuprofen, but not the subgroup randomized to naproxen. The OA subgroup receiving celecoxib experienced fewer clinically significant adverse GI events than the subgroups receiving ibuprofen or naproxen, with similar trends observed in patients with RA. Renal events were less common in the OA subgroup receiving treatment with celecoxib compared with the subgroup randomized to ibuprofen but not in the subgroup randomized to naproxen, and in RA patients, there were no differences between patients receiving the 3 drugs. These findings give providers, patients, and regulators a greater understanding of the relative safety of different NSAIDs (COX-2-selective and nonselective). Current safety information from the FDA regarding NSAIDs focuses on the risk of CV events and does not differentiate between agents. The results of the PRECISION trial and these subgroup analyses confirm that celecoxib does not increase the risk of CV events. However, celecoxib conferred slight reductions in the risk for several outcomes compared with other commonly used NSAIDs. Regulators and professional organizations might consider whether these data regarding differential safety across NSAIDs warrant new recommendations for the optimal use of the agents studied in the PRECISION trial.
